Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian

Inclusion Criteria: * Healthy. * Subject who completed the phase II Vi-DT study (Typhoid 0218) * Subjects/Parents have been informed properly regarding the study and signed the informed consent form. * Subject/parents/legal guardians will commit to comply with the instructions of the investigator and the schedule of the trial. Exclusion Criteria: * Subject concomitantly enrolled or scheduled to be enrolled in another trial. * Evolving mild, moderate or severe illness, especially infectious diseases or fever (axillary temperature ≥ 37.5oC). * Known history of allergy to any component of the vaccines. * History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection. * Any abnormality or chronic disease which according to the investigator might be compromised by the vaccination and/or interfere with the assessment of the trial objectives.